Today's diabetes market highlights the importance that individual stock selection still has in successful investing. While it may very well be generally true that overall sector movements explain a lot of an individual stock's performance, that has not been the case in this market. While the overall tone and tenor has been pretty negative, select names like Novo Nordisk (NYSE:NVO) and DexCom (Nasdaq:DXCM) have done quite well indeed.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

A Strong End to DexCom's Year
It has not all been smooth sailing for DexCom (the stock took a spanking late in 2010), but the company continues to build its emerging continuous glucose monitoring business. For the fourth quarter, total revenue increased 49%, while product revenue more than doubled from the year-ago level and rose 26% sequentially. DexCom also saw an encouraging jump in the sale of its start kits, to the tune of 24% sequential growth.

As the company increases its sales, it is beginning to see some operating leverage. Gross profit on product sales increased nearly five times (again, on a doubling of revenue) in the fourth quarter, when compared to the prior year. At the same time, the company has kept a lid on SG&A spending while still investing significant resources into R&D. All told, the company produced an operating loss more or less in line with the prior year's level.

The Look Ahead - Challenges and Opportunities
Going up against major companies in the continuous glucose monitoring field like Abbott Labs (NYSE:ABT) (which offers the Freestyle Navigator) and Medtronic (NYSE:MDT) (which sells the Guardian RT) has forced DexCom to look to partnerships to improve its chances of success, and there will likely be some activity on that frond this year.

Johnson & Johnson (NYSE:JNJ) has already applied for European approval of an insulin pump that integrates DexCom's CGM, and a U.S. filing could occur in the middle of this year. Likewise, a filing for an integrated device with Insulet (Nasdaq:PODD) could go into the FDA in the second half of the year. At the same time, the company continues to work on its own next-generation products, as well as a hospital-based product with Edwards Lifesciences (NYSE:EW) called the GlucoClear.

That is not to suggest it's all smooth sailing, though. Economic conditions and employment still matter, as the company is pointing to sequentially flat revenue due in part to the impact of the calendar year on potential customer's insurance deductibles. Elsewhere, a New England Journal of Medicine article cast doubt on the survival benefit of in-hospital intensive insulin therapy (a target market of the GlucoClear), and the aforementioned Abbott and Medtronic continue to push development of their own integrated devices and advanced sensors (Abbott is also working with Insulet on an integrated device).

The Market Rewards the Choosy
While the overall sluggish economy has crimped growth at the major players, the FDA has been an increasingly significant factor as well. MannKind (Nasdaq:MNKD) and Biodel (Nasdaq:BIOD) both suffered significant setbacks in the form of FDA rejection letters, and investors largely seem to believe that it will be increasingly difficult to secure approval for new medications and devices in the diabetes field. (For more, see MannKind And The FDA - Here We Go Again.)

That should work in the favor of companies like DexCom, Insulet and Novo Nordisk - companies that all have relatively new and effective products on the market for diabetes. Though these companies will need future FDA approvals to continue their growth trajectory, it is a bit less of a near-term risk than for them than many of its rivals.

The Bottom Line
In the meantime, investors should keep an eye on DexCom and Novo Nordisk in the hopes of a pullback; the valuations on both look stretched today, but both offer relatively rare growth in what is still a challenging healthcare market. (For more, see Measuring The Medicine Makers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Alternative Energy Stocks for 2016 (AMSC, SLTD)

    Follow a cautious approach when purchasing micro-cap stocks in the alternative energy sector. Learn about five alternative energy micro-caps worth considering.
  7. Stock Analysis

    Analyzing Porter's Five Forces on Under Armour (UA)

    Learn about Under Armour and how it differentiates itself in the competitive athletic apparel industry in light of the Porter's Five Forces Model.
  8. Stock Analysis

    The Biggest Risks of Investing in Qualcomm Stock (QCOM, BRCM)

    Understand the long-term fundamental risks related to investing in Qualcomm stock, and how financial ratios also play into the investment consideration.
  9. Stock Analysis

    The Biggest Risks of Investing in Johnson & Johnson Stock (JNJ)

    Learn the largest risks to investing in Johnson & Johnson through fundamental analysis and other potential risks. Also discover how JNJ compares to its peers.
  10. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
RELATED FAQS
  1. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  2. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  3. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  4. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  5. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
  6. What is the formula for calculating earnings per share (EPS)?

    Earnings per share (EPS) is the portion of a company’s profit that is allocated to each outstanding share of common stock, ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center